威尔逊氏症药物市场 - 全球产业规模、份额、趋势、机会和预测，按产品、配销通路、地区和竞争细分，2020-2030 年预测

2024 年全球威尔逊氏症药物市场价值为 6.105 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2030 年的复合年增长率为 5.50%。威尔逊氏症又称肝豆状核变性，是一种罕见的遗传性疾病，会影响人体代谢铜的能力。这种疾病是体染色体隐性遗传的，这意味着患病的个体会从父母双方各继承一个突变基因。威尔逊氏症会导致过量铜在各个器官（主要是肝臟和大脑）以及身体其他组织中积聚。威尔逊氏症可表现出多种症状，这使得诊断变得具有挑战性。常见症状和併发症包括肝病（肝炎、肝硬化）、神经系统问题（震颤、协调性和运动困难）、精神症状（性格变化、忧郁、焦虑）和眼部异常（Kayser-Fleischer 环，即角膜周围的绿色或褐色环）。威尔逊氏症的诊断通常包括血液检测（测量铜含量）、肝功能检测和基因检测（识别 ATP7B 基因的突变）。肝臟超音波或MRI等影像学研究也可用于评估肝臟中的铜堆积情况。

主要市场驱动因素

诊断方面的进展

主要市场挑战

抗药性

主要市场趋势

患者援助计划

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球威尔逊氏症药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品（螯合剂、矿物质）
  • 按配销通路（零售药局、医院药局、网路药局）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：亚太地区威尔逊氏症药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲威尔逊氏症药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美威尔逊氏症药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲威尔逊氏症药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲威尔逊氏症药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球威尔逊氏症药物市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• ANI Pharmaceuticals Inc.
• Apotex Inc
• AstraZeneca Plc
• Bausch Health Co. Inc.,
• Breckenridge Pharmaceutical Inc.
• Dr Reddys Laboratories Ltd.
• Endo International Plc
• Lupin Ltd.
• Merck and Co. Inc.
• Navinta LLC

第 17 章：策略建议

第18章调查会社について・免责事项

Global Wilson's Disease Drugs Market was valued at USD 610.50 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.50% through 2030. Wilson's Disease, also known as hepatolenticular degeneration, is a rare genetic disorder that affects the body's ability to metabolize copper. This condition is inherited in an autosomal recessive manner, meaning that an affected individual inherits two copies of the mutated gene, one from each parent. Wilson's Disease leads to the accumulation of excess copper in various organs, primarily the liver and brain, as well as other tissues in the body. Wilson's Disease can manifest with a wide range of symptoms, which can make diagnosis challenging. Common symptoms and complications include liver disease (hepatitis, cirrhosis), neurological problems (tremors, difficulty with coordination and movement), psychiatric symptoms (personality changes, depression, anxiety), and eye abnormalities (Kayser-Fleischer rings, which are green or brownish rings around the cornea). Diagnosis of Wilson's Disease typically involves blood tests to measure copper levels, liver function tests, and genetic testing to identify mutations in the ATP7B gene. Imaging studies like liver ultrasound or MRI may also be used to assess copper buildup in the liver.

Key Market Drivers

Advancements in Diagnosis

Genetic testing has become a cornerstone in the diagnosis of Wilson's Disease. Identifying mutations in the ATP7B gene, responsible for copper transport in the body, is a highly specific and reliable method for confirming the disease. For instance, according to the Wilson Disease Association, in May 2022, the FDA approved CUVRIOR (trientine tetrahydrochloride), marking the first new treatment for Wilson's disease in three decades. Advances in genetic testing techniques have made it more accessible and affordable. Non-invasive imaging techniques such as liver ultrasound and magnetic resonance imaging (MRI) have become valuable tools in assessing copper overload in the liver and other organs. These methods are less invasive than traditional liver biopsies and provide important diagnostic information. Laboratory tests measuring various markers related to copper metabolism in the blood and urine have become more sophisticated and informative. These markers include serum ceruloplasmin levels, 24-hour urinary copper excretion, and non-caeruloplasmin bound copper (NCC) measurements.

Key Market Challenges

Drug Resistance

Wilson's Disease requires lifelong treatment to maintain copper levels within a normal range. Patients often need to take medications, such as chelators like penicillamine or trientine, consistently over many years. Over time, some patients may develop resistance to the drugs they are taking. Drug resistance in Wilson's Disease means that the medications that were initially effective in lowering copper levels may become less so. This can result in a failure to adequately control copper accumulation in the body. In some cases, healthcare providers may need to increase the dosage of medications to overcome resistance. This can lead to higher doses and potentially an increased risk of side effects or adverse reactions. Maintaining consistent adherence to a lifelong treatment regimen can be challenging for patients, especially if they experience side effects or do not perceive a direct benefit from the medications. Poor adherence can contribute to treatment resistance. Detecting drug resistance requires close monitoring of copper levels in the body and the patient's response to treatment. Managing resistance often involves adjustments to the treatment plan, which can be complex and may require consultation with specialists. In cases of drug resistance, healthcare providers may explore alternative therapies or medications to manage Wilson's Disease. The availability and effectiveness of these alternatives can impact the market dynamics for Wilson's Disease drugs. Genetic factors can influence how a patient responds to treatment. Variations in genes related to copper metabolism can affect the effectiveness of certain medications and may contribute to resistance in some cases.

Key Market Trends

Patient Assistance Programs

APs aim to improve access to costly medications by providing financial assistance to patients who may otherwise have difficulty affording them. This is especially important for individuals with Wilson's Disease, as treatment can be expensive and lifelong. Patients with Wilson's Disease often require ongoing treatment, and the cost of medications and medical care can add up. PAPs can help alleviate the financial burden on patients and their families, making treatment more manageable. PAPs are particularly beneficial for individuals who are uninsured or underinsured, as they may face higher out-of-pocket costs for medications. These programs bridge the gap in coverage, ensuring that all eligible patients can access the drugs they need. Some PAPs offer co-pay assistance, covering a portion of the patient's out-of-pocket costs, including deductibles and co-pays. This can make it more affordable for patients to continue their treatment. Many PAPs provide educational resources and support to patients, helping them better understand their condition, treatment options, and how to navigate the healthcare system. PAPs often work to simplify the application process, making it easier for patients to enroll and receive assistance. Pharmaceutical companies that manufacture Wilson's Disease drugs may establish PAPs as part of their corporate social responsibility efforts or to support patients using their medications. Some PAPs collaborate with patient advocacy organizations focused on Wilson's Disease. These partnerships can help identify and reach eligible patients in need of assistance.

Key Market Players

• ANI Pharmaceuticals Inc.
• Apotex Inc.
• AstraZeneca Plc
• Bausch Health Co. Inc.
• Breckenridge Pharmaceutical Inc.
• Dr Reddy's Laboratories Ltd.
• Endo International Plc
• Lupin Ltd.
• Merck and Co. Inc.
• Navinta LLC

Report Scope:

In this report, the Global Wilson's Disease Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Wilson's Disease Drugs Market, By Product:

• Chelators
• Minerals

Wilson's Disease Drugs Market, By Distribution Channel:

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

Wilson's Disease Drugs Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Wilson's Disease Drugs Market.

Available Customizations:

Global Wilson's Disease Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Wilson's Disease Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Chelators, Minerals)
  • 5.2.2. By Distribution Channel (Retail pharmacies, Hospital pharmacies, Online pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Wilson's Disease Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Wilson's Disease Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. India Wilson's Disease Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Australia Wilson's Disease Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Distribution Channel
  • 6.3.4. Japan Wilson's Disease Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Distribution Channel
  • 6.3.5. South Korea Wilson's Disease Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Distribution Channel

7. Europe Wilson's Disease Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Wilson's Disease Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Wilson's Disease Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Spain Wilson's Disease Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Wilson's Disease Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. United Kingdom Wilson's Disease Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Distribution Channel

8. North America Wilson's Disease Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Wilson's Disease Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. Mexico Wilson's Disease Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Canada Wilson's Disease Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Distribution Channel

9. South America Wilson's Disease Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Wilson's Disease Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Wilson's Disease Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Wilson's Disease Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Wilson's Disease Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Wilson's Disease Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Wilson's Disease Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Wilson's Disease Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Wilson's Disease Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. ANI Pharmaceuticals Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Apotex Inc
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. AstraZeneca Plc
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Bausch Health Co. Inc.,
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Breckenridge Pharmaceutical Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Dr Reddys Laboratories Ltd.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Endo International Plc
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Lupin Ltd.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Merck and Co. Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10.Navinta LLC
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer